Brainstorm Cell Therapeutics (BCLI) Competitors $0.63 +0.01 (+1.77%) As of 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCLI vs. TENX, DYAI, MDCX, CVKD, RVPH, RLYB, NNVC, QTTB, FBLG, and NAIIShould you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Tenax Therapeutics (TENX), Dyadic International (DYAI), Medicus Pharma (MDCX), Cadrenal Therapeutics (CVKD), Reviva Pharmaceuticals (RVPH), Rallybio (RLYB), NanoViricides (NNVC), Q32 Bio (QTTB), FibroBiologics (FBLG), and Natural Alternatives International (NAII). These companies are all part of the "pharmaceutical products" industry. Brainstorm Cell Therapeutics vs. Its Competitors Tenax Therapeutics Dyadic International Medicus Pharma Cadrenal Therapeutics Reviva Pharmaceuticals Rallybio NanoViricides Q32 Bio FibroBiologics Natural Alternatives International Tenax Therapeutics (NASDAQ:TENX) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment. Do insiders and institutionals have more ownership in TENX or BCLI? 1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 3.1% of Tenax Therapeutics shares are owned by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to TENX or BCLI? In the previous week, Tenax Therapeutics had 14 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 16 mentions for Tenax Therapeutics and 2 mentions for Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 0.63 beat Tenax Therapeutics' score of -0.78 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Brainstorm Cell Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, TENX or BCLI? Tenax Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenax TherapeuticsN/AN/A-$17.60M-$0.92-6.57Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$3.10-0.20 Is TENX or BCLI more profitable? Brainstorm Cell Therapeutics' return on equity of 0.00% beat Tenax Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tenax TherapeuticsN/A -31.34% -30.39% Brainstorm Cell Therapeutics N/A N/A -519.50% Which has more volatility and risk, TENX or BCLI? Tenax Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Do analysts recommend TENX or BCLI? Tenax Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 181.46%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenax Therapeutics is more favorable than Brainstorm Cell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryTenax Therapeutics beats Brainstorm Cell Therapeutics on 8 of the 14 factors compared between the two stocks. Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCLI vs. The Competition Export to ExcelMetricBrainstorm Cell TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.96M$3.11B$5.74B$9.56BDividend YieldN/A2.23%4.53%4.08%P/E Ratio-0.1920.4030.4525.16Price / SalesN/A238.54392.5887.64Price / CashN/A42.3737.0358.50Price / Book-0.467.918.956.21Net Income-$11.62M-$54.72M$3.26B$265.38M7 Day Performance4.56%1.63%1.06%-1.13%1 Month Performance-15.87%5.86%4.31%-0.71%1 Year Performance-88.35%8.70%28.40%18.89% Brainstorm Cell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCLIBrainstorm Cell Therapeutics2.7436 of 5 stars$0.63+1.8%N/A-88.4%$6.96MN/A-0.1940Short Interest ↓Gap UpTENXTenax Therapeutics1.675 of 5 stars$6.01+0.7%$17.00+182.9%+44.4%$27.24MN/A-6.539Analyst RevisionDYAIDyadic International3.2494 of 5 stars$0.80+6.3%$6.00+654.6%-38.6%$27.08M$3.49M-4.187Gap DownMDCXMedicus Pharma1.8649 of 5 stars$2.00+2.0%$23.50+1,075.0%N/A$26.60MN/A-1.49N/ANews CoverageAnalyst RevisionHigh Trading VolumeCVKDCadrenal Therapeutics3.1611 of 5 stars$13.05+2.9%$32.00+145.2%+78.6%$25.95MN/A-1.474Short Interest ↑RVPHReviva Pharmaceuticals2.8449 of 5 stars$0.52-3.9%$7.17+1,280.3%-54.5%$25.92MN/A-0.805Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionRLYBRallybio3.0678 of 5 stars$0.62+3.4%$10.00+1,500.5%-45.4%$25.24M$640K-0.6640News CoverageShort Interest ↓NNVCNanoViricides0.7535 of 5 stars$1.53+2.0%N/A-25.1%$24.59MN/A-2.1220QTTBQ32 Bio2.5917 of 5 stars$2.04+3.6%$12.17+496.4%-95.3%$24.03M$1.16M-0.4739News CoverageShort Interest ↓Gap DownFBLGFibroBiologics2.9405 of 5 stars$0.62+7.6%$13.00+2,006.3%-55.8%$24.02MN/A-1.7110Short Interest ↑Gap UpNAIINatural Alternatives InternationalN/A$3.88+0.9%N/A-23.8%$23.73M$113.80M-2.79290Gap Down Related Companies and Tools Related Companies TENX Competitors DYAI Competitors MDCX Competitors CVKD Competitors RVPH Competitors RLYB Competitors NNVC Competitors QTTB Competitors FBLG Competitors NAII Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCLI) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access